操作建議
Kenvue Inc當前公司基本面數據相對健康,增長潛力很大。當前估值合理,在個人與家用產品服務行業排名20/36位。機構持股佔比非常高,近一個月多位分析師給出公司評級為持有。最高目標價19.55。中期看,股價處於平穩狀態。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議
財務指標
每股收益

由於公司未披露,未能獲取相關數據
營業總收入

由於公司未披露,未能獲取相關數據
Kenvue Inc簡介
Kenvue Inc. is a consumer health company. The Company’s differentiated portfolio of brands includes Tylenol, Neutrogena, Listerine, Johnson’s, BAND-AID, Aveeno, Zyrtec, and Nicorette. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee’s, ORSLTM, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women’s health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM).
公司代碼KVUE
公司Kenvue Inc
CEOPerry (Kirk L)
網址https://www.kenvue.com
常見問題
Kenvue Inc(KVUE)的當前股價是多少?
Kenvue Inc(KVUE)的當前股價是 17.330。
Kenvue Inc股票的52週最高點是25.170。
Kenvue Inc股票的52週最低點是14.020。
現在Kenvue Inc(KVUE)的股票是買入、持有還是賣出?
根據分析師評級,Kenvue Inc(KVUE)的總體評級為持有,目標價格為19.547。
Kenvue Inc(KVUE)股票的每股收益(EPS TTM)是多少
Kenvue Inc(KVUE)股票的每股收益(EPS TTM)是0.748。